A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Part of paid clinical trials in Kissimmee, Florida.

Sponsor
Pulmovant, Inc.
Study ID
NCT07333183
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Cardiovascular Diseases
  • Fibrosis
  • Interstitial Lung Disease (ILD)
  • Lung Diseases
  • Pulmonary Hypertension
  • Vascular Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • inhaled mosliciguat — DRUG
    Dose level 1, 2, or 3 for inhalation
  • Dry Powder Inhaler — DEVICE
    Dry powder inhaler for mosliciguat delivery

Study Details

This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.

Key Dates

Start date
Dec 23, 2025
Status verified
Apr 2026
Primary completion
Dec 31, 2026
Completion
Jan 31, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Active Comparator: inhaled mosliciguat
    Participants will receive inhaled mosliciguat daily for 16 weeks
  • Experimental: Extension: inhaled mosliciguat
    After Week 16, all participants will continue to receive inhaled mosliciguat through an Extension period

Primary Outcome Measure

Incidence and nature of participant TEAEs, SAEs, and AEs leading to discontinuation [ Time Frame: Baseline, Week 16 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLCKissimmeeFlorida34746
Guevara Lusmelys
[email protected]
407-507-2615

Find similar trials in Kissimmee, FL

By research site
Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC· Kissimmee, FL

Related Studies